Abstract
The aim of the present paper is to highlight the potential of nasal mucosa as an administration route for targeting the central nervous system, in particular, the brain. Among the formulation strategies for enhance nose to brain drug delivery, the use of colloidal carriers has became a revolutionary approach. These systems should be able to entrap drugs in the desired amount, to penetrate through anatomical barriers, to efficiently release the loaded drugs in the site of action and moreover to show a good physicochemical, biological stability and good biocompatibility. The use of vesicular systems (liposomes and niosomes) together with the use of micelles, in nose to brain delivery are here presented. Vesicle structure is characterized by the presence of a hydrophobic bilayer and an aqueous core that is absent in micelles. Amphiphilic molecules are responsible for soft nanocarriers formation, in particular: liposomes are formed by phospholipids, while niosomes by non-ionic surfactant and micelles by amphiphilic polymers.
Keywords: Intranasl delivery, nose-to-brain, central nervous system, liposomes, niosomes, micelles, polymerosomes.
Current Pharmaceutical Design
Title:Nose to Brain Delivery: New Trends in Amphiphile-Based “Soft” Nanocarriers
Volume: 21 Issue: 36
Author(s): Carlotta Marianecci, Federica Rinaldi, Patrizia N. Hanieh, Donatella Paolino, Luisa Di Marzio and Maria Carafa
Affiliation:
Keywords: Intranasl delivery, nose-to-brain, central nervous system, liposomes, niosomes, micelles, polymerosomes.
Abstract: The aim of the present paper is to highlight the potential of nasal mucosa as an administration route for targeting the central nervous system, in particular, the brain. Among the formulation strategies for enhance nose to brain drug delivery, the use of colloidal carriers has became a revolutionary approach. These systems should be able to entrap drugs in the desired amount, to penetrate through anatomical barriers, to efficiently release the loaded drugs in the site of action and moreover to show a good physicochemical, biological stability and good biocompatibility. The use of vesicular systems (liposomes and niosomes) together with the use of micelles, in nose to brain delivery are here presented. Vesicle structure is characterized by the presence of a hydrophobic bilayer and an aqueous core that is absent in micelles. Amphiphilic molecules are responsible for soft nanocarriers formation, in particular: liposomes are formed by phospholipids, while niosomes by non-ionic surfactant and micelles by amphiphilic polymers.
Export Options
About this article
Cite this article as:
Marianecci Carlotta, Rinaldi Federica, Hanieh N. Patrizia, Paolino Donatella, Marzio Di Luisa and Carafa Maria, Nose to Brain Delivery: New Trends in Amphiphile-Based “Soft” Nanocarriers, Current Pharmaceutical Design 2015; 21 (36) . https://dx.doi.org/10.2174/1381612821666150923095958
DOI https://dx.doi.org/10.2174/1381612821666150923095958 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Promises of Nanotechnology for Drug Delivery to Brain in Neurodegenerative Diseases
Current Nanoscience Emerging Therapies in the Treatment of Locally Advanced Squamous Cell Cancers of Head and Neck
Recent Patents on Anti-Cancer Drug Discovery Lipid based Nanocapsules: A Multitude of Biomedical Applications
Current Pharmaceutical Biotechnology The Neuroprotective Effect of Ginkgo biloba Leaf Extract and its Possible Mechanism
Central Nervous System Agents in Medicinal Chemistry Recent Patents on Biomedical Devices and Nanomaterials for Hyperthermal Therapy of Cancer
Recent Patents on Nanomedicine <i>DBX2</i> Promotes Glioblastoma Cell Proliferation by Regulating <i>REST</i> Expression
Current Pharmaceutical Biotechnology The Urokinase Receptor in the Central Nervous System
CNS & Neurological Disorders - Drug Targets The Significance of Transferrin Receptors in Oncology: the Development of Functional Nano-based Drug Delivery Systems
Current Drug Delivery Emerging Adenoviral Vectors for Stable Correction of Genetic Disorders
Current Gene Therapy Modulating the Hypoxia-Inducible Factor Signaling Pathway: Applications From Cardiovascular Disease to Cancer
Current Pharmaceutical Design Histidine Rich Glycoprotein, an Endogenous Regulator of Macrophage and Endothelial Biology
Current Angiogenesis (Discontinued) The Potential Targets and Mechanisms of a Carbazole and Pyrazole Containing Anticancer Compound
Current Cancer Drug Targets Using the Concept of Chous Pseudo Amino Acid Composition to Predict Enzyme Family Classes: An Approach with Support Vector Machine Based on Discrete Wavelet Transform
Protein & Peptide Letters Antisense Strategies in Therapy of Gliomas
Current Signal Transduction Therapy Nanotechnology Platforms in Diagnosis and Treatment of Primary Brain Tumors
Recent Patents on Nanotechnology The Exploitation of Toll-like Receptor 3 Signaling in Cancer Therapy
Current Pharmaceutical Design Malignant Mesothelioma Resistance to Apoptosis: Recent Discoveries and their Implication for Effective Therapeutic Strategies
Current Medicinal Chemistry Pharmacodynamics of Radiolabelled Anticancer Drugs for Positron Emission Tomography
Current Pharmaceutical Design Computational Insights into the Role of Glutathione in Oxidative Stress
Current Neurovascular Research Cannabinoids and Cardiovascular Disease: The Outlook for Clinical Treatments
Current Vascular Pharmacology